Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jeremy A L Lawrance"'
Autor:
Jen Jou Wong, Prakash Manoharan, Jon Bell, Damian Mullan, Jeremy A L Lawrance, Philip Borg, Amarjot Chander, Jill Tipping, Steve Jeans, Nicholas Lawrance
Publikováno v:
Journal of Clinical Interventional Radiology ISVIR. :089-097
Aim Flow redistribution is not uncommonly performed as a treatment strategy to optimize delivery of radioembolization particles to the liver. We quantitatively evaluated the effect of vessel embolization to promote flow redistribution when performing
Autor:
Jorge Barriuso, Christina Nuttall, Jeremy A L Lawrance, Was Mansoor, Richard A Hubner, Juan W. Valle, Angela Lamarca, Mairéad G McNamara, Damian Mullan
Publikováno v:
Nuttall, C, Lamarca, A, Mcnamara, M, Barriuso, J, Lawrance, J, Mullan, D, Mansoor, W, Valle, J W & Hubner, R A 2019, ' Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms : experience from a European Neuroendocrine Tumour Society centre of excellence ', Paper presented at UKINETS 2019, Birmingham, United Kingdom, 2/12/19 pp. 6 . https://doi.org/10.1530/endoabs.68.P6
Background: Hepatic arterial embolisation (HAE) is a recommended treatment option for patients with neuro-endocrine neoplasms (NENs) and liver metastasis. We aimed to describe outcomes after HAE for NENs at a single United Kingdom centre and investig
Autor:
Prakash Manoharan, P Arumugam, S Mullamitha, J. Bell, Damien Mullan, B Rajashanker, Vivek Misra, L Carter, A Sheen, D. Bentley, Sacha J Howell, Jeremy A L Lawrance, A Chittalia, T Westwood, Jill Tipping, F Farquharson, Gregory C. Wilson, Anne C. Armstrong, D Ryder, S. Jeans, H-U Laasch
Publikováno v:
Cancer Research. 78:P1-14
Background: SIRT is a globally licensed technique of Radio-Embolization (RE) of hepatic tumors via intra-arterial infusion of β-particle emitting Yttrium-90 (Y-90) radio-labelled microspheres. It increases response rates and hepatic time to progress
Autor:
Krzysztof C. Lewandowski, Jeremy A L Lawrance, Robert D Murray, Stephen M Shalet, Jan Komorowski, Harpal S. Randeva, Judith E. Adams
Publikováno v:
Growth Hormone & IGF Research. 21:96-101
Objective GHD adults exhibit a number of adverse surrogate markers of vascular risk culminating in excess vascular morbidity and mortality. Vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) have been implicated in the pat
Autor:
Maureen A. Zivanovic, G Wilson, Jill Tipping, Timothy M Illidge, Steve Jeans, Jeremy A L Lawrance, G Murphy, Hans-Ulrich Laasch, A Omed
Publikováno v:
Clinical Radiology. 65:720-728
Aim To evaluate the efficacy and safety of selective internal radiation therapy (SIRT). Materials and methods A retrospective analysis was undertaken of all patients who underwent SIRT at a single institution. Diagnostic and therapeutic angiograms, c
Autor:
Jill Tipping, M. Braun, Hans-Ulrich Laasch, Jeremy A L Lawrance, Saifee Mullamitha, F. Marti, Jurjees Hasan, P. Najran, S. Jeans, J. Bell, Mark N. K. Saunders, Gregory C. Wilson, Catherine McBain, D. Bentley, Prakash Manoharan, Damian Mullan, M. Nasralla, N. Alam, Thomas Westwood
Publikováno v:
Annals of Oncology. 29:v78
Publikováno v:
Clinical Endocrinology. 71:86-91
Summary Aims To evaluate the long-term efficacy and safety of pegvisomant as a treatment for acromegaly. Design Retrospective analysis of clinical and trial data from all patients treated with pegvisomant since 1997 at two centres with common protoco
Publikováno v:
Hormones (Athens, Greece). 15(1)
A male patient presented at the age of 54 years with metastatic pancreatic neuroendocrine tumour (NET). He was managed with interferon and multiple courses of MIBG therapy which controlled his disease for about seven years. He then developed symptoma
Publikováno v:
The British Journal of Radiology. 79:762-765
The aim of this study was to evaluate the success and complication rate of Nurse-led subclavian central venous catheter (CVC) insertion using the landmark technique. A prospective study was performed on all subclavian CVC insertion between 13/01/03 t
Autor:
Leif Håkansson, Meina Tang, Linda Wauk, C Mulatero, Malcolm R Ranson, John Wagstaff, Sandrine Marreaud, Lynn Broughton, Frederic Lehmann, Gordon C Jayson, D. Levitt, Manfred Herold, Alan Jackson, Jeremy A L Lawrance, Gerard Groenewegen, Jamal Zweit, Heinz Zwierzina
Publikováno v:
European Journal of Cancer. 41:555-563
We assessed the tolerability, safety, pharmacokinetics and dose-limiting toxicity (DLT) of the recombinant humanized IgG4 anti-vascular endothelial growth factor (VEGF) monoclonal antibody, HuMV833, in patients with advanced cancer. Cohorts of patien